Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists.

about

Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists.

Item

http://www.wikidata.org/entity/Q47148453

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Variability in the therapeutic ...... country survey of oncologists.

@en

Variability in the therapeutic ...... country survey of oncologists.

@nl

type

Item

label

Variability in the therapeutic ...... country survey of oncologists.

@en

Variability in the therapeutic ...... country survey of oncologists.

@nl

prefLabel

Variability in the therapeutic ...... country survey of oncologists.

@en

Variability in the therapeutic ...... country survey of oncologists.

@nl

P1476

Variability in the therapeutic ...... country survey of oncologists.

@en

P2093

Anna Perlaky

http://www.w3.org/2001/XMLSchema#string

Céline Audibert

http://www.w3.org/2001/XMLSchema#string

Daniel Glass

http://www.w3.org/2001/XMLSchema#string

P2860

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

Meta-analysis of BRCA1 and BRCA2 penetrance

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.

Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations.

Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.

Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.

P304

3471-3479

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S151420

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mark Stuntz

P577

2017-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29255348

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

5723112

http://www.w3.org/2001/XMLSchema#string